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Abstract
© 2018 American Association for Cancer Research. Purpose: The role of cholesterol biosynthesis
in hedgehog pathway activity and progression of hedgehog pathway medulloblastoma (Hh-MB)
were examined in vivo. Statins, commonly used cholesterol-lowering agents, were utilized to
validate  cholesterol  biosynthesis  as  a  therapeutic  target  for  Hh-MB.  Experimental  Design:
Bioinformatic  analysis  was  performed  to  evaluate  the  association  between  cholesterol
biosynthesis  with  hedgehog group medulloblastoma in  human biospecimens.  Alterations  in
hedgehog signaling were evaluated in  medulloblastoma cells  after  inhibition of  cholesterol
biosynthesis.  The progression of endogenous medulloblastoma in mice was examined after
genetic blockage of cholesterol biosynthesis in tumor cells. Statins alone, or in combination with
vismodegib (an FDA-approved Smoothened antagonist), were utilized to inhibit medulloblastoma
growth in vivo. Results: Cholesterol biosynthesis was markedly enhanced in Hh-MB from both
humans and mice. Inhibition of cholesterol biosynthesis dramatically decreased Hh pathway
activity  and  reduced  proliferation  of  medulloblastoma  cells.  Statins  effectively  inhibited
medulloblastoma growth in vivo and functioned synergistically in combination with vismodegib.
Conclusions:  Cholesterol  biosynthesis  is  required for  Smoothened activity  in  the hedgehog
pathway, and it is indispensable for the growth of Hh-MB. Targeting cholesterol biosynthesis
represents a promising strategy for treatment of Hh-MB.
http://dx.doi.org/10.1158/1078-0432.CCR-17-2923
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